Intrinsic value of Sangamo Therapeutics, Inc. - SGMO

Previous Close

$9.95

  Intrinsic Value

$2.27

stock screener

  Rating & Target

str. sell

-77%

Previous close

$9.95

 
Intrinsic value

$2.27

 
Up/down potential

-77%

 
Rating

str. sell

We calculate the intrinsic value of SGMO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  134
  208
  311
  451
  636
  874
  1,173
  1,540
  1,982
  2,503
  3,109
  3,801
  4,581
  5,451
  6,409
  7,455
  8,588
  9,805
  11,105
  12,485
  13,944
  15,480
  17,093
  18,780
  20,543
  22,382
  24,296
  26,288
  28,359
  30,512
Variable operating expenses, $m
  189
  288
  425
  613
  861
  1,180
  1,580
  2,072
  2,663
  3,361
  4,162
  5,089
  6,134
  7,298
  8,581
  9,982
  11,498
  13,128
  14,868
  16,716
  18,669
  20,726
  22,885
  25,145
  27,506
  29,967
  32,530
  35,197
  37,970
  40,852
Fixed operating expenses, $m
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  54
  56
  57
  58
  59
  61
  62
  63
  65
  66
  68
  69
  71
  72
  74
  75
  77
  79
Total operating expenses, $m
  231
  331
  469
  658
  907
  1,227
  1,628
  2,121
  2,713
  3,412
  4,214
  5,142
  6,188
  7,354
  8,638
  10,040
  11,557
  13,189
  14,930
  16,779
  18,734
  20,792
  22,953
  25,214
  27,577
  30,039
  32,604
  35,272
  38,047
  40,931
Operating income, $m
  -97
  -123
  -159
  -207
  -271
  -352
  -455
  -580
  -731
  -909
  -1,106
  -1,341
  -1,607
  -1,903
  -2,229
  -2,585
  -2,970
  -3,384
  -3,825
  -4,295
  -4,790
  -5,312
  -5,860
  -6,434
  -7,033
  -7,657
  -8,308
  -8,985
  -9,688
  -10,419
EBITDA, $m
  -83
  -107
  -139
  -183
  -241
  -315
  -409
  -523
  -659
  -821
  -1,008
  -1,222
  -1,463
  -1,732
  -2,028
  -2,351
  -2,700
  -3,076
  -3,477
  -3,903
  -4,353
  -4,827
  -5,324
  -5,845
  -6,389
  -6,955
  -7,546
  -8,160
  -8,799
  -9,462
Interest expense (income), $m
  0
  0
  7
  18
  33
  53
  79
  114
  156
  209
  273
  348
  435
  534
  646
  771
  909
  1,059
  1,222
  1,397
  1,584
  1,782
  1,992
  2,213
  2,444
  2,687
  2,940
  3,204
  3,480
  3,766
  4,063
Earnings before tax, $m
  -97
  -130
  -176
  -239
  -323
  -432
  -568
  -737
  -940
  -1,182
  -1,453
  -1,776
  -2,141
  -2,549
  -3,000
  -3,494
  -4,029
  -4,606
  -5,222
  -5,878
  -6,573
  -7,304
  -8,073
  -8,878
  -9,720
  -10,598
  -11,512
  -12,464
  -13,454
  -14,483
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -97
  -130
  -176
  -239
  -323
  -432
  -568
  -737
  -940
  -1,182
  -1,453
  -1,776
  -2,141
  -2,549
  -3,000
  -3,494
  -4,029
  -4,606
  -5,222
  -5,878
  -6,573
  -7,304
  -8,073
  -8,878
  -9,720
  -10,598
  -11,512
  -12,464
  -13,454
  -14,483

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  429
  663
  992
  1,440
  2,031
  2,792
  3,748
  4,921
  6,332
  7,998
  9,932
  12,143
  14,636
  17,414
  20,476
  23,819
  27,437
  31,325
  35,478
  39,887
  44,549
  49,457
  54,609
  60,001
  65,634
  71,507
  77,623
  83,987
  90,604
  97,481
Adjusted assets (=assets-cash), $m
  429
  663
  992
  1,440
  2,031
  2,792
  3,748
  4,921
  6,332
  7,998
  9,932
  12,143
  14,636
  17,414
  20,476
  23,819
  27,437
  31,325
  35,478
  39,887
  44,549
  49,457
  54,609
  60,001
  65,634
  71,507
  77,623
  83,987
  90,604
  97,481
Revenue / Adjusted assets
  0.312
  0.314
  0.314
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
  0.313
Average production assets, $m
  126
  195
  292
  424
  598
  822
  1,104
  1,449
  1,865
  2,356
  2,925
  3,576
  4,311
  5,129
  6,031
  7,015
  8,081
  9,226
  10,449
  11,748
  13,121
  14,567
  16,084
  17,672
  19,331
  21,061
  22,863
  24,737
  26,686
  28,711
Working capital, $m
  -109
  -168
  -252
  -365
  -516
  -709
  -951
  -1,249
  -1,607
  -2,030
  -2,521
  -3,082
  -3,715
  -4,420
  -5,198
  -6,046
  -6,965
  -7,952
  -9,006
  -10,125
  -11,308
  -12,554
  -13,862
  -15,231
  -16,661
  -18,152
  -19,704
  -21,320
  -22,999
  -24,745
Total debt, $m
  134
  329
  603
  975
  1,468
  2,102
  2,898
  3,875
  5,051
  6,439
  8,049
  9,891
  11,968
  14,282
  16,833
  19,617
  22,631
  25,870
  29,329
  33,002
  36,885
  40,974
  45,265
  49,757
  54,449
  59,341
  64,436
  69,737
  75,249
  80,978
Total liabilities, $m
  358
  553
  826
  1,199
  1,692
  2,326
  3,122
  4,099
  5,275
  6,663
  8,273
  10,115
  12,192
  14,506
  17,057
  19,841
  22,855
  26,094
  29,553
  33,226
  37,109
  41,198
  45,489
  49,981
  54,673
  59,565
  64,660
  69,961
  75,473
  81,202
Total equity, $m
  72
  111
  166
  240
  339
  466
  626
  822
  1,058
  1,336
  1,659
  2,028
  2,444
  2,908
  3,419
  3,978
  4,582
  5,231
  5,925
  6,661
  7,440
  8,259
  9,120
  10,020
  10,961
  11,942
  12,963
  14,026
  15,131
  16,279
Total liabilities and equity, $m
  430
  664
  992
  1,439
  2,031
  2,792
  3,748
  4,921
  6,333
  7,999
  9,932
  12,143
  14,636
  17,414
  20,476
  23,819
  27,437
  31,325
  35,478
  39,887
  44,549
  49,457
  54,609
  60,001
  65,634
  71,507
  77,623
  83,987
  90,604
  97,481
Debt-to-equity ratio
  1.870
  2.970
  3.640
  4.060
  4.330
  4.510
  4.630
  4.720
  4.780
  4.820
  4.850
  4.880
  4.900
  4.910
  4.920
  4.930
  4.940
  4.950
  4.950
  4.950
  4.960
  4.960
  4.960
  4.970
  4.970
  4.970
  4.970
  4.970
  4.970
  4.970
Adjusted equity ratio
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167
  0.167

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -97
  -130
  -176
  -239
  -323
  -432
  -568
  -737
  -940
  -1,182
  -1,453
  -1,776
  -2,141
  -2,549
  -3,000
  -3,494
  -4,029
  -4,606
  -5,222
  -5,878
  -6,573
  -7,304
  -8,073
  -8,878
  -9,720
  -10,598
  -11,512
  -12,464
  -13,454
  -14,483
Depreciation, amort., depletion, $m
  14
  16
  19
  24
  29
  37
  46
  58
  72
  88
  98
  119
  144
  171
  201
  234
  269
  308
  348
  392
  437
  486
  536
  589
  644
  702
  762
  825
  890
  957
Funds from operations, $m
  -83
  -114
  -157
  -216
  -294
  -395
  -522
  -679
  -869
  -1,094
  -1,356
  -1,657
  -1,997
  -2,378
  -2,799
  -3,260
  -3,760
  -4,298
  -4,874
  -5,487
  -6,135
  -6,819
  -7,537
  -8,289
  -9,075
  -9,896
  -10,750
  -11,640
  -12,564
  -13,526
Change in working capital, $m
  -41
  -59
  -83
  -114
  -150
  -193
  -243
  -298
  -358
  -423
  -491
  -561
  -633
  -705
  -777
  -848
  -919
  -987
  -1,054
  -1,119
  -1,183
  -1,246
  -1,308
  -1,369
  -1,430
  -1,491
  -1,553
  -1,615
  -1,680
  -1,746
Cash from operations, $m
  -42
  -55
  -74
  -102
  -144
  -202
  -279
  -381
  -510
  -671
  -865
  -1,096
  -1,364
  -1,673
  -2,022
  -2,411
  -2,841
  -3,311
  -3,820
  -4,367
  -4,952
  -5,573
  -6,229
  -6,920
  -7,646
  -8,405
  -9,198
  -10,024
  -10,885
  -11,780
Maintenance CAPEX, $m
  -3
  -4
  -7
  -10
  -14
  -20
  -27
  -37
  -48
  -62
  -79
  -98
  -119
  -144
  -171
  -201
  -234
  -269
  -308
  -348
  -392
  -437
  -486
  -536
  -589
  -644
  -702
  -762
  -825
  -890
New CAPEX, $m
  -47
  -69
  -97
  -132
  -174
  -224
  -281
  -346
  -416
  -491
  -570
  -651
  -734
  -818
  -902
  -984
  -1,066
  -1,145
  -1,223
  -1,299
  -1,373
  -1,446
  -1,517
  -1,588
  -1,659
  -1,730
  -1,801
  -1,874
  -1,949
  -2,026
Cash from investing activities, $m
  -50
  -73
  -104
  -142
  -188
  -244
  -308
  -383
  -464
  -553
  -649
  -749
  -853
  -962
  -1,073
  -1,185
  -1,300
  -1,414
  -1,531
  -1,647
  -1,765
  -1,883
  -2,003
  -2,124
  -2,248
  -2,374
  -2,503
  -2,636
  -2,774
  -2,916
Free cash flow, $m
  -92
  -128
  -177
  -244
  -332
  -446
  -588
  -764
  -974
  -1,224
  -1,513
  -1,844
  -2,218
  -2,635
  -3,095
  -3,597
  -4,141
  -4,726
  -5,351
  -6,014
  -6,716
  -7,456
  -8,232
  -9,045
  -9,894
  -10,779
  -11,701
  -12,661
  -13,658
  -14,695
Issuance/(repayment) of debt, $m
  134
  195
  274
  373
  493
  634
  796
  977
  1,176
  1,388
  1,611
  1,842
  2,077
  2,314
  2,550
  2,784
  3,014
  3,239
  3,459
  3,673
  3,883
  4,089
  4,291
  4,492
  4,692
  4,892
  5,095
  5,301
  5,512
  5,729
Issuance/(repurchase) of shares, $m
  124
  169
  231
  314
  422
  559
  728
  933
  1,176
  1,460
  1,776
  2,145
  2,557
  3,013
  3,511
  4,052
  4,633
  5,255
  5,916
  6,615
  7,351
  8,124
  8,933
  9,779
  10,660
  11,579
  12,534
  13,527
  14,559
  15,631
Cash from financing (excl. dividends), $m  
  258
  364
  505
  687
  915
  1,193
  1,524
  1,910
  2,352
  2,848
  3,387
  3,987
  4,634
  5,327
  6,061
  6,836
  7,647
  8,494
  9,375
  10,288
  11,234
  12,213
  13,224
  14,271
  15,352
  16,471
  17,629
  18,828
  20,071
  21,360
Total cash flow (excl. dividends), $m
  165
  236
  328
  443
  583
  747
  936
  1,147
  1,377
  1,624
  1,874
  2,143
  2,416
  2,692
  2,967
  3,239
  3,507
  3,768
  4,024
  4,274
  4,518
  4,757
  4,993
  5,226
  5,459
  5,692
  5,928
  6,167
  6,413
  6,665
Retained Cash Flow (-), $m
  -124
  -169
  -231
  -314
  -422
  -559
  -728
  -933
  -1,176
  -1,460
  -1,776
  -2,145
  -2,557
  -3,013
  -3,511
  -4,052
  -4,633
  -5,255
  -5,916
  -6,615
  -7,351
  -8,124
  -8,933
  -9,779
  -10,660
  -11,579
  -12,534
  -13,527
  -14,559
  -15,631
Prev. year cash balance distribution, $m
  322
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  363
  67
  97
  129
  161
  188
  208
  214
  201
  164
  98
  -3
  -141
  -321
  -544
  -813
  -1,127
  -1,487
  -1,892
  -2,341
  -2,833
  -3,367
  -3,941
  -4,553
  -5,202
  -5,887
  -6,606
  -7,360
  -8,146
  -8,966
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  348
  62
  84
  106
  124
  137
  140
  134
  116
  86
  46
  -1
  -54
  -108
  -160
  -206
  -245
  -274
  -291
  -297
  -293
  -279
  -258
  -232
  -202
  -172
  -142
  -114
  -89
  -68
Current shareholders' claim on cash, %
  50.2
  27.1
  15.5
  9.2
  5.6
  3.5
  2.3
  1.5
  1.0
  0.6
  0.4
  0.3
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

FINANCIAL RATIOS  of  Sangamo Therapeutics, Inc. (SGMO)

Valuation Ratios
P/E Ratio -9.8
Price to Sales 37.1
Price to Book 5.2
Price to Tangible Book
Price to Cash Flow -10.7
Price to Free Cash Flow -10.5
Growth Rates
Sales Growth Rate -52.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -50%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 2.9%
Total Debt to Equity 2.9%
Interest Coverage 0
Management Effectiveness
Return On Assets -38.4%
Ret/ On Assets - 3 Yr. Avg. -23.3%
Return On Total Capital -43.4%
Ret/ On T. Cap. - 3 Yr. Avg. -26.6%
Return On Equity -43.9%
Return On Equity - 3 Yr. Avg. -26.8%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -373.7%
EBITDA Margin - 3 Yr. Avg. -180.2%
Operating Margin -384.2%
Oper. Margin - 3 Yr. Avg. -186%
Pre-Tax Margin -378.9%
Pre-Tax Margin - 3 Yr. Avg. -183.5%
Net Profit Margin -378.9%
Net Profit Margin - 3 Yr. Avg. -179.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 3.6%
Payout Ratio 0%

SGMO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SGMO stock intrinsic value calculation we used $84 million for the last fiscal year's total revenue generated by Sangamo Therapeutics, Inc.. The default revenue input number comes from 0001 income statement of Sangamo Therapeutics, Inc.. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SGMO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SGMO is calculated based on our internal credit rating of Sangamo Therapeutics, Inc., is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Sangamo Therapeutics, Inc..
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SGMO stock the variable cost ratio is equal to 145.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $41 million in the base year in the intrinsic value calculation for SGMO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Sangamo Therapeutics, Inc..

Corporate tax rate of 27% is the nominal tax rate for Sangamo Therapeutics, Inc.. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SGMO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SGMO are equal to 94.1%.

Life of production assets of 43.7 years is the average useful life of capital assets used in Sangamo Therapeutics, Inc. operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SGMO is equal to -81.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $366.518 million for Sangamo Therapeutics, Inc. - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 102.273 million for Sangamo Therapeutics, Inc. is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Sangamo Therapeutics, Inc. at the current share price and the inputted number of shares is $1.0 billion.

RELATED COMPANIES Price Int.Val. Rating
BIIB Biogen Inc. 239.09 418.24  buy
LGND Ligand Pharmac 111.89 156.42  buy
XLRN Acceleron Phar 40.18 1.39  str.sell
ONCE Spark Therapeu 105.07 3.26  str.sell
AMGN Amgen Inc. 187.11 157.83  hold

CONTACT US      

About X-FIN       Privacy policy       Terms of use      

Copyright © X-FIN.com 2005-2019. All rigths reserved.